Sander Markx from Columbia University: Charting a New Future in Targeted Psychiatric Care

Video

Studying the use of targeted medicines in psychiatry is still new but early studies have shown that this could be a viable treatment option in the future for some patients in need.

Studying the use of targeted medicines in psychiatry is still new but early studies have shown that this could be a viable treatment option in the future for some patients in need.

While most medications to treat psychiatric conditions are meant to address patient symptoms they are not all directed toward a cure for the respective conditions. Although he was not ready to say that targeted therapies could provide a cure for some of these conditions and patients Sander Markx, MD, from Columbia University said there is evidence that this field could provide a new level of treatment not seen in current traditional patient care.

Related Videos
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
© 2024 MJH Life Sciences

All rights reserved.